August 10, 2006 -- Cephalon received a “Not Approvable” letter for ADHD drug Sparlon; Encysive won European approval for Thelin, its treatment for PAH; ImClone did not find a buyer for the company; Threshold will fire one-third of its staff; Oscient sold Canadian rights for its antibiotic Factive to Abbott; MGI Pharma won Orphan status for Dacogen for leukemia; CuraGen began a Phase I test of its cancer drug against advanced solid tumors; Gene Logic will provide the FDA with its genomics data and software; a journal article said Lipitor from Pfizer reduced the incidence of a follow-up stroke or heart attacks; and Advancis Pharma said Pulsys, its amoxicillin antibiotic, met all of its endpoints in a Phase III trial against strep throat. The Centient Biotech 200™ was off by 3 points at 3600.57, a drop of .09%. More details...
